Skip to content
DataLookout
Menu

Myelofibrosis clinical trials

Get alerts when Myelofibrosis trials change
Data updated daily from ClinicalTrials.gov, last refresh 2026-11-22

What changed in the last 30 days

17 trials changed in the last 30 days: 2 stopped, 9 with notable changes, 6 with minor changes only.

  1. Stopped: Two Step Haplo With Radiation Conditioning Recruitment suspended Thomas Jefferson UniversityPhase 2 NCT05031897
  2. Minor: MANIFEST-3 · Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF) Trial sites expanded: 168 → 174 locations Novartis PharmaceuticalsPhase 3 NCT07357727
  3. Notable: ZE74-0282 · JAK2 V617F- or Calreticulin-Mutated Hematologic Disorders Recruitment opened Eilean TherapeuticsPhase 1 NCT07529951
  4. Minor: Fedratinib · DIPSS (Dynamic International Prognostic Scoring System)- Intermediate or High-risk Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (Post-PV MF), or Post-essential Thrombocythemia Myelofibrosis (Post-ET MF) Trial completed Bristol-Myers SquibbPhase 1/2 NCT04446650
  5. Minor: ELRISE MF · Elritercept to Placebo · Myelofibrosis and Anemia Who Are Taking Ruxolitinib Trial sites expanded: 195 → 214 locations TakedaPhase 3 NCT07623161
  6. Stopped: Hu8F4 · Advanced Hematologic Malignancies Trial terminated M.D. Anderson Cancer CenterPhase 1 NCT02530034
  7. Notable: cAMeLot-1 · Bleximenib · Acute Leukemia Primary completion pushed from Feb 26, 2027 to Dec 29, 2028 Janssen Research & Development, LLCPhase 1/2 NCT04811560
  8. Minor: ODYSSEY · Momelotinib in Combination With Luspatercept · Transfusion Dependent Myelofibrosis Study completion pushed from Mar 17, 2028 to Jan 31, 2029 GlaxoSmithKlinePhase 2 NCT06517875
  9. Notable: PHEMOP · Functional and Phenotypic Characterization of Monocytes in Myeloproliferative Syndromes Primary completion pushed from Nov 19, 2026 to May 29, 2027 University Hospital, AngersNot applicable NCT06361641
  10. Minor: PRT12396 · Select Myeloproliferative Neoplasms Trial sites expanded: 18 → 22 locations Prelude Therapeutics IncorporatedPhase 1 NCT07469891
  11. Notable: JAK-PeriMF · Use of Gecacitinib · Myeloid Malignancies and Myelofibrosis During the Peri-transplant Period Following Allogeneic Hematopoietic Stem Cell Transplantation Recruitment opened Ruijin HospitalPhase 1/2 NCT07883382
  12. Notable: Extended Access of Momelotinib · Myelofibrosis Primary endpoint(s) modified GlaxoSmithKlinePhase 2 NCT03441113
  13. Notable: Selinexor and Pacritinib in JAK Inhibitor-naïve MF · Cytopenias Recruitment opened John MascarenhasPhase 2 NCT07447817
  14. Minor: CLARITY-101 · DMR-001 · CALR-mutant Myeloproliferative Neoplasms Trial sites expanded: 4 → 36 locations Damora TherapeuticsPhase 1 NCT07849231
  15. Notable: Treating Anemia in Myelofibrosis With Repurposed Drugs (Nelfinavir) That Restore Iron Delivery to the Bone Marrow Primary completion pushed from Jun 2026 to Jun 2027 University of California, IrvinePhase 1/2 NCT07281781
  16. Notable: Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant Primary and study completion dates pushed to Feb 14, 2030 City of Hope Medical CenterPhase 1 NCT07020533
  17. Notable: CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors · CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant Primary completion moved earlier from Jan 1, 2028 to Jan 1, 2027 City of Hope Medical CenterPhase 2 NCT06059391
  • Stopped: terminated, suspended or withdrawn
  • Notable: the plan changed
  • Minor: routine updates

New sponsor entrants, last 90 days sponsors with their first trial in this area

First postedTrialSponsorPhase
2026-11-16 NCT07938580 Gecacitinib Plus Luspatercept in Patients With Myelofibrosis and Anemia Peking Union Medical College Hospital new Phase 2
2026-11-02 NCT07909733 Maintenance Treatment With Imetelstat in Patients With High-Risk Myeloid Neoplasms After… University of Wisconsin, Madison new Phase 1
2026-10-20 NCT07883382 An Exploratory Study on the Use of Gecacitinib in Patients With Myeloid Malignancies and… Ruijin Hospital new Phase 1/2
2026-10-07 NCT07863466 MPNdpoint. Single-center, Retrospective, Prospective Study of the Outcome of Patients… Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico new

Active trials by phase

Early Phase 1
3
Phase 1
41
Phase 1/2
17
Phase 2
43
Phase 2/3
1
Phase 3
13
Phase 4
2
Not charted: 43 active trials with no phase listed on ClinicalTrials.gov (typically behavioural, device, procedure and observational studies).
Get alerts when Myelofibrosis trials change
Status changes, date slips, and new sponsor entrants: detected daily, delivered to your inbox.
Start monitoring free